Anti-tumor effect of thalidomide and paclitaxel on hepatocellular carcinoma in nude mice

Chinese Medical Journal

Volumn 118, Issue 20, 2005, Pages 1688-1694

  Zhang, Zhong Lin ^a   Liu, Zhi Su ^a   Sun, Quan ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

?Thalidomide; Carcinoma; Hepatocellular; Neovascularization; Paclitaxel; Pathologic

Indexed keywords

CARBOXYMETHYLCELLULOSE; CD34 ANTIGEN; MESSENGER RNA; PACLITAXEL; PLACEBO; THALIDOMIDE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LUNG METASTASIS; MALE; METASTASIS POTENTIAL; MICROVASCULATURE; MOUSE; NONHUMAN; NUDE MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD34; CELL LINE, TUMOR; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THALIDOMIDE; TRANSPLANTATION, HETEROLOGOUS;

EID: 27744513354     PISSN: 03666999     EISSN: 03666999     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Sakoda LC, Graubard BI, Evans AA, et al. Toenail selenium and risk of hepatocellular carcinoma mortality in Haimen City, China. Int J Cancer 2005;115:618-24.
2. Cai JQ, Hu JQ, Che X, et al. Prognosis of primary liver carcinoma treated with local resection. Chin Med J 2003;116:187-190.
3. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(6 Suppl 16):15-18.
4. Cha C, Dematteo RP. Molecular mechanisms in hepatocellular carcinoma development. Best Pract Res Clin Gastroenterol 2005;19:25-37.
5. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003;3:643-651.
6. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91:4082-4085.
7. Kruse FE, Joussen AM, Rohrschneider K, et al. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998;236:461-466.
8. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64: 971-978.
9. Li X, Liu X, Wang J, et al. Thalidomide downregulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res 2003;23(3B):2481-2487.
10. Vacca A, Scavelli C, Montefusco V, et al. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 2005;23:5334-5346.
11. Meierhofer C, Dunzendorfer S, Weidermann CJ. Thoretical basis for the acting of thalidomide. Bio Drugs 2001;15:681-703.
12. Tseng JE, Glisson BS, Khuri FR, et al. Phase II study of antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 2001;92:2364-2373.
13. Govindarajan R. Irinotecan and thalidomide in metastatic colorectal cancer. Oncology 2000; 14 (12 Suppl 13):29-32.
14. Baidas SM, Winer EP, Fleming GF, et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000;18:2710-2717.
15. Limat S, Woronoff-Lemsi MC, Menat C, et al. From randomised clinical trials to clinical practice: a pragmatic cost-effectiveness analysis of Paclitaxel in first-line therapy for advanced ovarian cancer. Pharmacoeconomics 2004;22:633-641.
16. Fountzilas G, Pectasides D, Kalogera-Fountzila A, et al. Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat 2005;92:1-9.
17. Long BH, Fairchild CR. Paclitaxel inhibits progression of mitotic cells to G1 phase by interference with spindle formation without affecting other microtubule functions during anaphase and telephase. Cancer Res 1994;54: 4355-4361.
18. Wang J, Lou P, Lesniewski R, et al. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer drugs 2003;14:13-19.
19. Shimamura T, Saito S, Morita K, et al. Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15:640-646.
20. Zhao JJ, Hu JQ, Cai JQ, et al. Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma. Chin Med J 2003;116:772-776.
21. Poon RT, Ng IO, Lau C, et al. Correlation of serum basic growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. Am J Surg 2001;182:298-304.
22. Li Y, Tang Y, Ye L, et al. Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastisis-related genes through cDNA microarray. J Cancer Res Clin Oncol 2003;129:43-51.
23. Kotoh T, Dhar DK, Masunaga R, et al. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery 1999;125:536-544.
24. Myoung H, Hong SD, Kim YY, et al. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma. Cancer Lett 2001;163:191-200.
25. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
26. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-18.
27. Gutman M, Szold A, Ravid A, et al. Failure of thalidomide to inhibit tumor growth and angiogenesis in viva. Anticancer Res 1996;16(6B):3673-3677.
28. Patt YZ, Hassan MM, Lozano RD, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 2005; 103: 749-755.
29. Morabito A, Carillio G, Longo R, et al. Thalidomide is inactive in heavily pretreated patients with metastatic breast cancer. Cancer J 2005;11:248-251.
30. Belo AV, Ferreira MA, Bosco AA, et al. Differential effects of thalidomide on angiogenesis and tumor growth in mice. Inflammation 2001;25:91-96.
31. Stephens TD, Bunde CJ, Fillmore BJ. Mechanism of action in thalidomide teratogenesis. Biochem Pharmacol 2000;59:1489-1499.
32. Patt YZ, Hassan MM, Lozano RD, et al. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 2000;23:319-321.
33. Santos-Mendoza T, Favila-Castillo L, Oltra A, et al. Thalidomide and its metabolites have no effect on human lymphocyte proliferation. Int Arch Allery Immunol 1996;111:13-17.
34. Imura S, Miyake H, Izumi K, et al. Correlation of vascular endothelial cell proliferation with microvessel density and expression of vascular endothelial growth factor and basic fibroblast growth factor in hepatocellular carcinoma. J Med Invest 2004;51(34):202-209.
35. Hotchkiss KA, Ashton AW, Mahmood R, et al. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther 2002; 1:1191-1200.
36. Fujii T, Tachibana M, Dhar DK, et al. Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice. Anticancer Res 2003;23(3B):2405-2411.